Top 15 blockbuster drugs with patent expiration in the next 10 years

TextPickup

SourceMedical Rubik's Cube Info

Recently, FiercePharma, a foreign biomedical website, published an article introducing 15 blockbuster drugs whose patents will expire in the next 10 years

Moody analysts wrote in a recent report that in the next few years, nine of the top 20 drugs in the industry will lose their exclusivity

Mike Levesque, an employee of Moody and the lead author of the report, said that these drugs may be protected by numerous patents, so it is difficult to accurately predict when competition will begin to heat up

However, this list provides a brief introduction to global multi-billion-dollar drugs that are about to compete with generic drugs or biosimilars, which will undoubtedly force pharmaceutical manufacturers to focus on their research projects or other companies in order to find future importance.

Levesque told FiercePharma.

Of course, the most concerned is AbbVie's Humira, the world's highest-selling drug will face competition from US biosimilars starting in 2023, and Amgen will receive the first copy right

Then there is Merck’s Keytruda.

How important are these drugs to pharmaceutical companies? Humira generated about 43% of revenue for AbbVie last year, while Keytruda generated about 30% of revenue for Merck

However, in the short term, Merck will deal with the patent cliff issue of its older product type 2 diabetes drug Januvia (sitagliptin) and its combination therapy Janumet (sitagliptin + metformin)

As Revlimid, Eliquis, and Opdivo face competition, BMS is the drug maker that has lost the most monopoly drugs in the past decade

Moody believes that there will be no more large-scale mergers and acquisitions like BMS's acquisition of Celgene-at least in the short term